Literature DB >> 2838433

An improved generator for the production of 212Pb and 212Bi from 224Ra.

R W Atcher1, A M Friedman, J J Hines.   

Abstract

We have developed an improved generator for the production of the alpha emitting radionuclide 212Bi and its parent, 212Pb. These radionuclides are well suited to use as radiotherapeutic agents due to their relatively short half lives and appropriate particle particle emissions. The parent, 224Ra, is available from a long-lived parent and can be isolated on a generator which produces the daughters in good yield and low breakthrough. The 212Bi can be eluted by itself or in equilibrium with its parent.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2838433     DOI: 10.1016/0883-2889(88)90016-0

Source DB:  PubMed          Journal:  Int J Rad Appl Instrum A        ISSN: 0883-2889


  16 in total

Review 1.  An overview of targeted alpha therapy.

Authors:  Young-Seung Kim; Martin W Brechbiel
Journal:  Tumour Biol       Date:  2011-12-06

Review 2.  Targeted alpha-therapy: past, present, future?

Authors:  Martin W Brechbiel
Journal:  Dalton Trans       Date:  2007-09-11       Impact factor: 4.390

3.  Efficient bifunctional decadentate ligand 3p-C-DEPA for targeted α-radioimmunotherapy applications.

Authors:  Hyun A Song; Chi Soo Kang; Kwamena E Baidoo; Diane E Milenic; Yunwei Chen; Anzhi Dai; M W Brechbiel; Hyun-Soon Chong
Journal:  Bioconjug Chem       Date:  2011-05-23       Impact factor: 4.774

Review 4.  Chemical aspects of metal ion chelation in the synthesis and application antibody-based radiotracers.

Authors:  Eszter Boros; Jason P Holland
Journal:  J Labelled Comp Radiopharm       Date:  2018-03-12       Impact factor: 1.921

Review 5.  Cancer radioimmunotherapy with alpha-emitting nuclides.

Authors:  Olivier Couturier; Stéphane Supiot; Marie Degraef-Mougin; Alain Faivre-Chauvet; Thomas Carlier; Jean-François Chatal; François Davodeau; Michel Cherel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05       Impact factor: 9.236

6.  Application of 212Pb for Targeted α-particle Therapy (TAT): Pre-clinical and Mechanistic Understanding through to Clinical Translation.

Authors:  Kwon Yong; Martin Brechbiel
Journal:  AIMS Med Sci       Date:  2015-08-18

7.  Towards translation of 212Pb as a clinical therapeutic; getting the lead in!

Authors:  Kwon Yong; Martin W Brechbiel
Journal:  Dalton Trans       Date:  2011-03-04       Impact factor: 4.390

Review 8.  Unconventional nuclides for radiopharmaceuticals.

Authors:  Jason P Holland; Matthew J Williamson; Jason S Lewis
Journal:  Mol Imaging       Date:  2010-02       Impact factor: 4.488

Review 9.  Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight".

Authors:  Romain Eychenne; Michel Chérel; Férid Haddad; François Guérard; Jean-François Gestin
Journal:  Pharmaceutics       Date:  2021-06-18       Impact factor: 6.321

10.  Ra-224 activity, half-life, and 241 keV gamma ray absolute emission intensity: A NIST-NPL bilateral comparison.

Authors:  Denis E Bergeron; Sean M Collins; Leticia Pibida; Jeffrey T Cessna; Ryan Fitzgerald; Brian E Zimmerman; Peter Ivanov; John D Keightley; Elisa Napoli
Journal:  Appl Radiat Isot       Date:  2020-12-31       Impact factor: 1.513

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.